drugset / Trial / NCT02020616
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide ER | Unknown | 2 mg | Subcutaneous |
| Subject | LY3053102 | Unknown | 7 mg | Subcutaneous |
| Subject | LY3053102 | Unknown | 200 mg | Subcutaneous |
| Background | Metformin | Small molecule | — | Oral |